Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Gelesis

Request full access

Biotechnology company developing first-in-class therapeutics to safely treat obese, overweight, and diabetic patients

Calimera, ItalyFounded 2006Biotech & Life Sciences

About Gelesis

Gelesis is a biotechnology company focused on developing innovative therapies for gastrointestinal (GI) related chronic diseases. The company's proprietary platform features the first and only superabsorbent hydrogel made exclusively from naturally derived building blocks. Gelesis primarily serves adults who are overweight or obese, with a Body Mass Index (BMI) of 25 to 40, by offering products like PLENITY, which aids in weight management when combined with diet and exercise. The company operates in the healthcare and biotechnology market, targeting conditions such as Non-Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic Steatohepatitis (NASH), Type 2 diabetes, and Chronic Idiopathic Constipation (CIC). Gelesis generates revenue through the sale of its hydrogel-based therapies and continues to expand its pipeline of potential treatments for various GI-related conditions.

Source: Dealroom company data

At a glance

Status
Listed
Listing
Public via SPAC 2021

Gelesis in the Calimera ecosystem

Live from Dealroom

The Gelesis office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

13 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • BIRD Foundation

Series A3 investors entered at this stage

Series B and later9 investors entered at this stage

  • Cormorant Asset Management
  • Invesco
  • Vitruvian Partners
  • China Medical System Holdings
  • PV Capital Management
  • Pacific investment Management
  • Kennedy Lewis Investment Management
  • Capstar Special Purpose Acquisition Corp
  • Theras
Team profiled 15 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Patents

Estimated portfolio value
$47M

18 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

See Gelesis on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.